How FDA Will Take Away A ‘Breakthrough’ Designation
Executive Summary
Process for rescinding designation under the expedited regulatory pathway will begin with an internal FDA multidisciplinary meeting and review division director agreement on an intent-to-rescind decision.
You may also be interested in...
Breakthrough Therapies: Another Drug’s Approval Should Not Lead To De Facto Rescission, Industry Says
Industry and patient advocacy groups urge the agency to consider a variety of factors in determining whether a drug’s breakthrough designation should be rescinded upon the approval of another product; draft guidance language on quality of clinical evidence to be considered in rescission decisions raises concerns specific to rare disease populations.
US FDA’s First Competitive Generic Therapy Approval Comes With A Twist
Apotex’s potassium chloride oral solution is eligible for 180-day exclusivity under new expedited pathway even though Amneal’s generic referencing same product was approved three weeks earlier; Amneal's continued marketing will not be blocked by Apotex’s exclusivity, which is forfeited if it fails to launch within 75 days.
US FDA’s First Competitive Generic Therapy Approval Comes With A Twist
Apotex’s potassium chloride oral solution is eligible for 180-day exclusivity under new expedited pathway even though Amneal’s generic referencing same product was approved three weeks earlier; Amneal's continued marketing will not be blocked by Apotex’s exclusivity, which is forfeited if it fails to launch within 75 days.